Acts on hypothalamic appetite circuits, reducing energy intake.
What was measuredSTEP 1 (n≈1,961, adults without diabetes): mean weight loss ≈15% at 68 weeks vs ≈2.4% on placebo.
Also known as GLP-1 receptor agonist · developed by Novo Nordisk
Licensed by at least one major regulator for a specific indication, on the strength of completed phase 3 trials. Approval is for that indication in that population — it is not a general endorsement of the compound.
A long-acting analogue of GLP-1, a hormone the gut releases after eating. Structural changes — an Aib substitution that resists enzymatic breakdown, and a fatty acid chain that binds albumin — extend its half-life from minutes to about a week.
Agonist at the GLP-1 receptor. Increases glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and acts on hypothalamic appetite circuits. The weight effect appears to be driven mainly by reduced energy intake.
The STEP programme reported mean weight loss around 15% at 68 weeks versus roughly 2.4% on placebo, in participants without diabetes. Effect sizes were smaller in participants with type 2 diabetes.
SELECT enrolled over 17,000 participants with established cardiovascular disease and overweight or obesity, but without diabetes, and reported a roughly 20% reduction in major adverse cardiovascular events over about three years. This is among the strongest outcome data for any weight-management drug.
The SUSTAIN trials established HbA1c reductions that met or exceeded active comparators, which is the basis of its original licence.
This is a summary of what has been reported in the literature, not a complete safety profile. For anything concerning your own health, speak to a doctor.
Licensed for type 2 diabetes (Ozempic, Rybelsus) and weight management (Wegovy). Prescription-only in the UK, EU and US. Compounded and unlicensed versions have been linked to dosing errors and hospitalisations, and regulators including the MHRA and FDA have issued warnings about them.
The sites below are where Semaglutide is understood to act, paired with what was actually measured there and in whom. A site on this diagram means a compound acts there — not that a benefit is established.
Drag to turn · tap an organ
Acts on hypothalamic appetite circuits, reducing energy intake.
What was measuredSTEP 1 (n≈1,961, adults without diabetes): mean weight loss ≈15% at 68 weeks vs ≈2.4% on placebo.
GLP-1 receptor agonism increases glucose-dependent insulin secretion and suppresses glucagon.
What was measuredSUSTAIN programme: HbA1c reductions meeting or exceeding active comparators in type 2 diabetes. This is the basis of the original licence.
Slows gastric emptying.
What was measuredMeasured directly in human pharmacodynamic studies. Contributes to satiety, and to the nausea that led a meaningful minority of trial participants to stop.
Cardiovascular outcome benefit in an at-risk population.
What was measuredSELECT (n>17,000, established cardiovascular disease without diabetes): ≈20% reduction in major adverse cardiovascular events over about three years.
A single molecule that activates two incretin receptors — GIP and GLP-1 — built on a GIP backbone with substitutions tha…
An investigational agonist at three receptors — GIP, GLP-1 and glucagon. The glucagon component is what distinguishes it…
A fragment of the C-terminus of human growth hormone, developed specifically as a weight-loss drug on the theory that th…
This site publishes summaries of published research. It is not medical advice, and Genexis Health does not sell or supply any compound described here. Please confirm each statement below to continue.
We ask everyone to confirm they understand this site is information rather than medical advice before reading it. Because you have not confirmed those statements, you cannot continue.
If you are looking for health advice or treatment, please speak to a licensed healthcare professional. Nothing on this site is a substitute for that.